Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

February 06, 2026 — 09:47 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous sarcoidosis.

Currently, ROIV is trading at $24.92, up 17.88 percent, over the previous close of 21.14 on the Nasdaq. The stock opened at $23.97 and has climbed as high as $25.49 so far in today's session. Over the past year, it has traded in a range of $8.73 to $25.49.

In the study, brepocitinib significantly improved disease activity, achieving a 22.3-point improvement in mean Cutaneous Sarcoidosis Activity and Morphology Instrument - Activity (CSAMI-A) score at Week 16, compared with a 0.7-point improvement with placebo. The treatment showed rapid and sustained improvements across other efficacy measures with a consistent safety profile.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

Tags

Latest Articles